Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sequential subcutaneous interleukin-2 and interferon alfa followed by sorafenib in unresectable or metastatic renal cell carcinoma
2005-003697-25Phase 2Active
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Dec 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib, aldesleukin and interferon alfa in renal cell carcinoma (RCC), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoints: Median progression-free survival and Time to progression. Started Dec 2005; status: active.
02
Drugs
sorafenibaldesleukininterferon alfa
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2005-003697-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003697-25.